Allergic heparin hypersensitivity – recommendations for diagnostic work up and patient management
Tóm tắt
Heparins are unproblematic drugs from an allergist’s perspective, since despite frequent application heparin hypersensitivity is quite rarely in clinical routine. This article provides an overview of selected scientific articles and is based on a literature search in PubMed and specialist databases. Most commonly, heparin allergic patients develop lymphocyte-mediated, eczematous local reactions directly at the injection sites (usually on the lower abdomen) hours to days after initiating regular subcutaneous heparin injections. The high sensitivity of skin-prick and intradermal testing procedures means that subcutaneous provocation tests are seldom necessary for diagnosis. The “compartment allergy” phenomenon is a particular feature of heparin-induced local allergic reactions. Here, the route of application determines whether an allergic inflammatory reaction develops. In case of heparin-allergic individuals, injections into the subcutaneous tissue cause eczematous plaques, whereas intravenous injections or infusions are well tolerated. Since the introduction of low molecular weight heparin preparations, the incidence of potentially life-threatening heparin-induced thrombocytopenia caused by activating IgG (Ig: immunoglobulin) antibodies against heparin-platelet factor 4 (PF4) complexes on platelet membranes has declined. IgE-mediated heparin allergy with immediate-type anaphylactic reactions seems to be extremely rare.
Tài liệu tham khảo
Klein GF, Kofler H, Wolf H, Fritsch PO. Eczema-like, erythematous, infiltrated plaques: a common side effect of subcutaneous heparin therapy. J Am Acad Dermatol. 1989;21(4 Pt 1):703–7.
Trautmann A, Seitz CS. Heparin allergy: delayed-type non-IgE-mediated allergic hypersensitivity to subcutaneous heparin injection. Immunol Allergy Clin North Am. 2009;29:469–80.
Seitz CS, Bröcker EB, Trautmann A. Management of allergy to heparins in postoperative care: subcutaneous allergy and intravenous tolerance. Dermatol Online J. 2008;14:4.
Warkentin TE, Roberts RS, Hirsh J, Kelton JG. Heparin-induced skin lesions and other unusual sequelae of the heparin-induced thrombocytopenia syndrome: a nested cohort study. Chest. 2005;127:1857–61.
Anders D, Trautmann A. Allergic anaphylaxis due to subcutaneously injected heparin. Allergy Asthma Clin Immunol. 2013;9:1.
Brockow K, Garvey LH, Aberer W, Atanaskovic-Markovic M, Barbaud A, Bilo MB, et al. Skin test concentrations for systemically administered drugs—an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013;68:702–12.
Boehncke WH, Weber L, Gall H. Tolerance to intravenous administration of heparin and heparinoid in a patient with delayed-type hypersensitivity to heparins and heparinoids. Contact Derm. 1996;35:73–5.
Trautmann A, Bröcker EB, Klein CE. Intravenous challenge with heparins in patients with delayed-type skin reactions after subcutaneous administration of the drug. Contact Derm. 1998;39:43–4.
Jappe U, Reinhold D, Bonnekoh B. Arthus reaction to lepirudin, a new recombinant hirudin, and delayed-type hypersensitivity to several heparins and heparinoids, with tolerance to its intravenous administration. Contact Derm. 2002;46:29–32.
Gaigl Z, Pfeuffer P, Raith P, Bröcker EB, Trautmann A. Tolerance to intravenous heparin in patients with delayed-type hypersensitivity to heparins: a prospective study. Br J Haematol. 2005;128:389–92.
Trautmann A, Kleine-Tebbe J. Allergologie in Klinik und Praxis. Stuttgart: Thieme; 2017.